Copyright
©2010 Baishideng.
World J Gastroenterol. Jun 28, 2010; 16(24): 3025-3032
Published online Jun 28, 2010. doi: 10.3748/wjg.v16.i24.3025
Published online Jun 28, 2010. doi: 10.3748/wjg.v16.i24.3025
Table 1 Mean prevalence of HCV infection, HBV infection, alcohol abuse and DM2 in the free living population of the Pordenone area and controls in this study
General population (%) | Control group of the study (%) | ||
Global | 60-75 yr age interval | ||
HCV positive | 3.2 | 5.0 | 5.3 |
HBV positive | 1.2 | 1.7 | 1.2 |
Alcohol abuse | 4.5 | 5.0 | 4.7 |
DM2 | 4.8 | 12.4 | 12.6 |
Table 2 Characteristics of patients in the HCC, LC and control groups n (%)
HCC n = 465 | LC n = 618 | Controls n = 490 | P | |
Sex, male | 364 (78.3) | 450 (72.8) | 385 (78.6) | 0.1706 |
Alcohol abuse | 233 (51.2) | 312 (50.6) | 23 (4.7) | < 0.0001 |
DM2 | 145 (31.2) | 144 (23.2) | 62 (12.6) | < 0.0001 |
ALT ≥ 53 IU/L | 113 (24.3) | 150 (24.3) | N/A | 0.9911 |
HBV positive | 39 (8.4) | 39 (6.3) | N/A | 0.1908 |
HCV positive | 268 (57.6) | 285 (46.1) | N/A | 0.0002 |
Table 3 Association of DM2 with HCC: results of multivariate analyses using controls and LC subjects as comparison groups
OR | 95% CI | P | |
Control group | |||
Age ≥ 65 yr | 0.873 | 0.606-1.259 | 0.4675 |
BMI ≥ 25 kg/m2 | 1.048 | 0.769-1.426 | 0.7681 |
Alcohol abuse | 22.069 | 13.749-35.425 | < 0.0001 |
DM2 | 2.507 | 1.703-3.692 | < 0.0001 |
LC group | |||
Age ≥ 65 yr | 2.457 | 1.855-3.252 | < 0.0001 |
BMI ≥ 25 kg/m2 | 1.560 | 1.197-2.032 | 0.0010 |
HBV positive | 2.372 | 1.363-4.127 | 0.0022 |
HCV positive | 2.783 | 1.896-4.084 | < 0.0001 |
Alcohol abuse | 1.937 | 1.318-2.845 | 0.0008 |
ALT ≥ 53 IU/L | 0.919 | 0.672-1.256 | 0.5951 |
DM2 | 1.456 | 1.072-1.979 | 0.0162 |
Table 4 Biochemical characteristics of diabetic HCC, LC patients and controls, DM2 duration and therapy (mean ± SD)
HCC (n = 145) | LC (n = 144) | Controls (n = 62) | P | |
BMI (kg/m2) (median) | 25.6 ± 2.9 (26.0) | 25.8 ± 3.8 (25.0) | 25.1 ± 2.4 (25.3) | 0.3175a |
Cholesterol (mg/dL) (median) | 155.4 ± 47.4 (152) | 155.9 ± 37.7 (155) | 160.6 ± 45.4 (173.0) | 0.6013a |
Triglycerides (mg/dL) (median) | 110.6 ± 60.7 (94.5) | 108.0 ± 45.5 (101.5) | 111.5 ± 67.9 (95.0) | 0.8060a |
Fasting plasma glucose (mg/dL) (median) | 126.7 ± 47.3 (110.5) | 109.3 ± 32.9 (100.0) | 98.0 ± 20.6 (95.0) | < 0.0001a |
Current HbA1c (%) (median) | 7.5 ± 1.8 (7.3) | 6.6 ± 1.5 (6.4) | 6.8 ± 1.5 (6.5) | 0.0001a |
Average past HbA1c (%) (range) | 7.7 ± 1.5 (4-13.5) | N/A | N/A | |
DM2 duration (mo) (median) | 141.6 ± 81.0 (146) | 135.4 ± 98.3 (117) | 124.9 ± 100.5 (119) | 0.2496a |
Therapy, n (%) | < 0.0001b | |||
Not reported | 0 (0) | 12 (8.3) | 2 (3.2) | |
Metformin | 13 (9.0) | 39 (27.1) | 15 (24.2) | |
Sulphonylureas | 68 (46.9) | 33 (22.9) | 32 (51.6) | |
Insulin | 64 (44.1) | 60 (41.7) | 13 (21.0) |
Table 5 Association of antidiabetic therapy, metabolic control and DM2 duration with HCC among diabetic patients: results of multivariate analyses using controls and LC subjects as comparison groups
OR1 | 95% CI | P | |
Control group | |||
Sex, male | 1.860 | 0.636-5.441 | 0.2574 |
Age ≥ 65 yr | 0.225 | 0.071-0.715 | 0.0115 |
BMI ≥ 25 kg/m2 | 0.888 | 0.364-2.166 | 0.7936 |
Alcohol abuse | 16.155 | 4.798-54.389 | < 0.0001 |
Triglycerides (mg/dL, continuous) | 1.001 | 0.994-1.008 | 0.8097 |
Cholesterol (mg/dL, continuous) | 1.003 | 0.994-1.013 | 0.4890 |
Metformin vs sulphonylureas | 0.149 | 0.039-0.507 | 0.0054 |
Insulin vs sulphonylureas | 1.243 | 0.459-3.366 | 0.6686 |
DM2 duration (mo, continuous) | 1.001 | 0.996-1.005 | 0.6740 |
HbA1c % (continuous) | 1.265 | 0.943-1.699 | 0.1172 |
LC group | |||
Sex, male | 0.120 | 0.0051-0.278 | < 0.0001 |
Age ≥ 65 yr | 1.508 | 0.719-3.165 | 0.2774 |
BMI ≥ 25 kg/m2 | 1.473 | 0.716-3.029 | 0.2928 |
HBV+ | 3.535 | 0.428-29.184 | 0.2410 |
HCV+ | 2.870 | 1.129-7.293 | 0.0267 |
Alcohol abuse | 1.455 | 0.567-3.732 | 0.4351 |
ALT ≥ 53 IU/L | 0.808 | 0.394-1.675 | 0.5606 |
Triglycerides (mg/dL, continuous) | 1.002 | 0.995-1.008 | 0.6366 |
Cholesterol (mg/dL, continuous) | 1.003 | 0.995-1.011 | 0.4012 |
Metformin vs sulphonylureas | 0.163 | 0.057-0.462 | 0.0006 |
Insulin vs sulphonylureas | 0.428 | 0.203-0.901 | 0.0255 |
DM2 duration (mo, continuous) | 1.001 | 0.997-1.005 | 0.6723 |
HbA1c % (continuous) | 1.508 | 1.197-1.899 | 0.0005 |
- Citation: Donadon V, Balbi M, Valent F, Avogaro A. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. World J Gastroenterol 2010; 16(24): 3025-3032
- URL: https://www.wjgnet.com/1007-9327/full/v16/i24/3025.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i24.3025